Stock listing
A0DNJ3 Stock Price, News, Filings & Events — Neurizon Therapeutics Limited
Selected listing: A0DNJ3 · LS · EUR · DE
This page tracks Neurizon Therapeutics Limited's A0DNJ3:LS listing on LS in EUR for DE, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following A0DNJ3:LS. A0DNJ3:LS is the stock-level entry point for investors researching Neurizon Therapeutics Limited, while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary.
- Ticker
- A0DNJ3:LS
- Asset type
- Stock
- Market cap
- $33.4M
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- Exchange
- LS
- Currency
- EUR
Neurizon Therapeutics Limited A0DNJ3:LS stock context
This page tracks Neurizon Therapeutics Limited's A0DNJ3:LS listing on LS in EUR for DE, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following A0DNJ3:LS. A0DNJ3:LS is the stock-level entry point for investors researching Neurizon Therapeutics Limited, while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary.
Latest news from Neurizon Therapeutics Limited
Appendix 4E and 2026 Annual Report
August 25, 2026
Neurizon Enters Strategic R&D Financing Facility
July 31, 2026
HEALEY ALS Platform Trial Regimen I enrolment completed - Topline results for NUZ-001 accelerated to Q2 CY2027
July 16, 2026
Neurizon executes long-term supply agreement with Elanco
June 16, 2026
HEALEY ALS Trial Surpasses 50% Dosing Ahead of Schedule
June 11, 2026
Research Neurizon Therapeutics Limited
Neurizon Therapeutics Limited investor report
Review AI stock analysis and investor report context for A0DNJ3:LS.
Neurizon Therapeutics Limited company profile
View the public company page for Neurizon Therapeutics Limited on 6ix.
Neurizon Therapeutics Limited news
Read company news and market updates connected to Neurizon Therapeutics Limited.
Neurizon Therapeutics Limited investor events
Find investor webinars, events, and replay context for Neurizon Therapeutics Limited.
Alternate listings
NUZ:ASX
AU · AUD
Alternate listing for Neurizon Therapeutics Limited; the primary context on this page is A0DNJ3:LS.
A40STF:LSX
DE · EUR
Alternate listing for Neurizon Therapeutics Limited; the primary context on this page is A0DNJ3:LS.
A40STF:LS
DE · EUR
Alternate listing for Neurizon Therapeutics Limited; the primary context on this page is A0DNJ3:LS.
A0DNJ3:LSX
DE · EUR
Alternate listing for Neurizon Therapeutics Limited; the primary context on this page is A0DNJ3:LS.
ECQ0:FWB
DE · EUR
Alternate listing for Neurizon Therapeutics Limited; the primary context on this page is A0DNJ3:LS.
NUZTF:OTC
US · USD
Alternate listing for Neurizon Therapeutics Limited; the primary context on this page is A0DNJ3:LS.
ECQ0:SWB
DE · EUR
Alternate listing for Neurizon Therapeutics Limited; the primary context on this page is A0DNJ3:LS.